Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 8Phase EARLY_PHASE1 2Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Genitourinary 14Gastrointestinal 11CNS 10Thoracic 9Breast 8Gynecologic 7Dermatologic 6Plasma cell 5Sarcoma 4Tumor-Agnostic 2Other hematologic neoplasm 2Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1

Conditions

Paraganglioma 1Neuroendocrine Tumors 1Neuroblastoma 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Magnetic Resonance Spectroscopy × Endocrine × Clear all
NCT02177773 2019-11-12

DOTA-TOC

University of California, San Francisco

Phase 1/2 Terminated
300 enrolled 5 charts
CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡